Head-To-Head Survey: Nexalin Technology (NASDAQ:NXL) vs. Nexeon Medsystems (OTCMKTS:NXNN)

Nexalin Technology (NASDAQ:NXL) and Nexeon Medsystems (OTCMKTS:NXNN) are both business services companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nexalin Technology and Nexeon Medsystems, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	1	0	0	2.00
Nexeon Medsystems	0	0	0	0	0.00

Nexalin Technology presently has a consensus price target of $3.00, suggesting a potential upside of 4.17%. Given Nexalin Technology’s stronger consensus rating and higher probable upside, equities analysts clearly believe Nexalin Technology is more favorable than Nexeon Medsystems.

Valuation and Earnings

This table compares Nexalin Technology and Nexeon Medsystems”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$110,000.00	348.22	-$4.65 million	($0.64)	-4.50
Nexeon Medsystems	N/A	N/A	N/A	N/A	N/A

Nexeon Medsystems has lower revenue, but higher earnings than Nexalin Technology.

Profitability

This table compares Nexalin Technology and Nexeon Medsystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,407.98%	-187.59%	-167.21%
Nexeon Medsystems	N/A	N/A	N/A

Insider & Institutional Ownership

0.7% of Nexalin Technology shares are owned by institutional investors. 24.0% of Nexalin Technology shares are owned by insiders. Comparatively, 61.2% of Nexeon Medsystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Nexalin Technology has a beta of 4.24, suggesting that its stock price is 324% more volatile than the S&P 500. Comparatively, Nexeon Medsystems has a beta of 6.98, suggesting that its stock price is 598% more volatile than the S&P 500.

Summary

Nexeon Medsystems beats Nexalin Technology on 5 of the 9 factors compared between the two stocks.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.